Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CACA 2025 | Emerging treatment strategies and trial challenges in nasopharyngeal carcinoma

Yupei Chen • 6 Nov 2025
CACA 2025
Head and Neck Cancer

Yupei Chen, MD, Sun Yat-sen University Cancer Center, Guangzhou, China, comments on recently updates in nasopharyngeal carcinoma (NPC), which is prevalent in Southern China. Novel metronomic chemotherapy regimens and enhanced classification systems will reduce metastasis rates, but enrollment criteria for trials remain a challenge. This interview took place at the 2025 Chinese Anti-Cancer Association (CACA) Science & Technology Award Talks in Kunming, China.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

Phase II study of FID-007 plus cetuximab in recurrent or metastatic HNSCC
1:04
Phase II study of FID-007 plus cetuximab in recurrent or metastatic HNSCC
Jacob Thomas • 31 May 2026
TARGET-HPV: neoadjuvant HPV16-targeted immunotherapy in oropharyngeal cancer
2:24
TARGET-HPV: neoadjuvant HPV16-targeted immunotherapy in oropharyngeal cancer
Ari Rosenberg • 31 May 2026
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
3:11
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
Nabil Saba • 1 Jun 2026
INO-3107 and B-cell immunity: implications for HPV-associated cancers
1:29
INO-3107 and B-cell immunity: implications for HPV-associated cancers
Nabil Saba • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals